within Pharmacolibrary.Drugs.ATC.C;

model C02DG01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 55 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pinacidil is a vasodilator drug acting as an ATP-sensitive potassium channel opener. It was primarily developed for the management of hypertension but is now largely obsolete and not in widespread clinical use. Pinacidil causes relaxation of vascular smooth muscle, leading to decreased blood pressure.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic data found for pinacidil in humans. Parameters are estimated based on its chemical class, typical drug characteristics, and secondary references.</p><h4>References</h4><ol><li><p>Ahnfelt-Rønne, I (1988). Pinacidil. Preclinical investigations. <i>Drugs</i> 36 Suppl 7 4–9. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198800367-00003&quot;>10.2165/00003495-198800367-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3076134/&quot;>https://pubmed.ncbi.nlm.nih.gov/3076134</a></p></li><li><p>Eilertsen, E, et al., &amp; Arrigoni-Martelli, E (1982). Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 12(3) 177–185. DOI:<a href=&quot;https://doi.org/10.3109/00498258209046792&quot;>10.3109/00498258209046792</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7113254/&quot;>https://pubmed.ncbi.nlm.nih.gov/7113254</a></p></li><li><p>Laher, MS, &amp; Hickey, MP (1985). Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers. <i>The Journal of international medical research</i> 13(3) 159–162. DOI:<a href=&quot;https://doi.org/10.1177/030006058501300302&quot;>10.1177/030006058501300302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4007251/&quot;>https://pubmed.ncbi.nlm.nih.gov/4007251</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02DG01;
